Glioblastoma multiforme (GBM or World Health Organization (WHO) grade IV) is the most malignant tumor of the brain. Despite conventional combination treatment of surgery, radiotherapy and chemotherapy, the survival of patients with GBM is generally o1 year. It is a great challenge to identify an effective drug that could efficiently inhibit (i) the growth of cancer cells; (ii) angiogenesis; (iii) metastasis; (iv) tumor-associated inflammation; (v) inactivate proliferative signal, (vi) induce specific apoptosis, and yet causes minimal harm to normal cells. Mesenchymal stem cells (MSCS) do possess some unique features (inherent tumor tropism; anti-inflammatory and immunosuppressive properties) that are not commonly found in current anticancer agents. These cells are known to secrete a vast array of proteins including growth factors, cytokines, chemokines and so on that regulate their biology in an autocrine or paracrine manner in accordance to the surrounding microenvironment. This review briefly summarizes the biology of MSCs and discusses their properties and new development for brain cancer treatment.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. 1 The current standard of care includes surgical debulking of the tumor, followed by radiation and chemotherapy typically with temozolomide (TMZ). Over the years, new strategies have been developed with varying extent of therapeutic efficacy. For example, an inhibitor targeting the PI3K pathway could enhance the therapeutic efficacy in combination with death receptor-and chemotherapy-induced apoptosis in glioma cells, 2 whereas combination therapies such as TMZ or irinotecan with bevacizimab have similar efficacy to bevacizumab alone in recurrent GBM patients. 3 Other antineoplastic agents such as irenotecan and topotecan are also being evaluated, although many of these agents do not penetrate well through the bloodbrain barrier and high doses of systemically delivered drugs are often required to reach sufficient brain tumor concentrations. So far, GBM has retained its dismal prognosis with a median survival at best for 1 year at initial diagnosis and B6 months after recurrence. 4 The failure of current therapeutic approaches to treat gliomas is attributed primarily to the highly infiltrating and heterogeneous nature of these neoplasms. These malignant cells are often seen surrounding the neurons and blood vessels (also known as perineuronal and perivascular satellitosis) 5 and migrate through the white matter tracts to regions distant from the original tumor mass. 6 The lack of defined tumor margin makes complete surgical resection difficult; not to mention, some of these migratory cells could temporarily exit the cell cycle during migration, thus making them resistant to therapies that target dividing cells. 7 Alternate mechanism underlying resistance to therapy and the recurrent phenotype of GBM tumors is thought to be attributed by the presence of glioma stem cells. 8 These cells are defined to exhibit self-renewal ability ex vivo or in vivo, have the capacity to generate non-tumorigenic and exhibit altered karyotype and multilineage differentiation abilities. 9 CD133 (also known as prominin-1) and other markers such as nestin, SOX2, Bmi1, Musashi, CD44, CD15 and A2B5 have been used as markers for glioma stem cells. 10 Thus, there is much interest in the development of novel approaches to address this clinical need. In this review, we will focus on innovative therapeutic approaches using stem cells, in particular mesenchymal stem cells (MSCs), to treat human gliomas.
MESENCHYMAL STEM CELLS
Mesenchymal stem cells or mesenchymal stromal cells (MSCs) were first identified in the bone marrow more than 40 years ago.
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These cells constitute a rare population of plastic-adherent, nonhematopoietic stromal cells (B0.0001-0.001% of the nucleated cells) in the bone marrow and were later identified in many tissues such as brain, 12 adipose tissue, 13 lung, 14 heart, 15 umbilical cord, 16 fetal tissues 17 and other organs. MSCs are identified according to the criteria set forth by the International Society for Cell Therapy (ISCT; 2006) that described MSCs as plastic-adherent cells, negative for the hematopoietic markers CD45 and CD34, monocyte and macrophage marker CD14, and HLA-DR. MSCs are positive for expression markers including CD73 (known as ecto 5'nucleotidase and originally recognized by the monoclonal antibody (MAb) SH3/4), CD105 (known as endoglin and originally recognized by the MAb SH2) and CD90 (Thy-1), and differentiate into adipocytes, chondrocytes and osteoblasts under standard in vitro differentiating conditions. 18 They are relatively easy to isolate and propagate to clinical scale. 19 The multipotent potential of MSCs renders them an excellent cell source for regenerative medicine. MSCs have been used in clinical trials for the treatment of myocardial infarction [20] [21] [22] and spinal cord injury 23, 24 in children with severe osteogenesis imperfect 25, 26 and Parkinson's disease. 27 MSCs are poorly immunogenic due to low expressions of MHC class I and absence of MHC class II, 28 making it ideal for treating inflammation-associated disorders such as graftversus-host disease 29 and Crohn's disease.
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TUMOR TROPISM OF MSCs
In the field of cancer therapy, the most attractive feature of MSCs is their inherent ability to migrate towards tumor cells or 'a wound that never heals'. Migration of MSCs to tumors has been demonstrated in malignant glioma, 32 43 indicating that this phenomenon is independent of the type of tumor. This attraction is thought to be mediated through paracrine signaling loop between the chemoattractants from the tumor microenvironment and the expression of the corresponding receptors in MSC or vice versa. We have demonstrated that the interaction of proteases with their corresponding receptors is critical in mobilizing MSC to migrate to the tumors. Specifically, the matrix metalloproteinase-1 (MMP-1) could mediate MSC migration through its interaction with its cognate receptor, proteaseactivated receptor-1 (PAR-1), and the blockade of MMP-1/PAR-1 interaction abolish tumor tropism of both adults 44 and fetal 45 MSCs. Tumor tropism of MSCs could also be mediated through crosstalk activities between MMP-1/PAR-1 and other signaling axes (as illustrated in Figure 1 ). Smadja et al. 46 have shown that PAR-1 activation could promote CXCR4-dependent migration in human endothelial progenitor cells. Recent findings from our laboratory (manuscript in preparation) demonstrated that SDF-1/ CXCR4-mediated MSC migration is MMP-1 dependent; upregulation of MMP-1 activities was detected upon SDF-1/CXCR4 binding, and decreased when the cells were treated with AMD3100, a CXCR4 inhibitor. These results thus suggest that the MMP-1/PAR-1 axis acts directly with SDF-1/CXCR-4 axis to mobilize MSCs.
The ability of these MSCs to track microscopic tumors have significant clinical potential as these cells may potentially be employed for tracking or targeting metastasis and tumors that are inaccessible for resection. As a consequence, many research strategies have been developed to modify MSCs as a cargo for therapeutic gene carrier. In brain tumor preclinical animal models, these include using cytokines such as interleukin-12; 47 interferonb 48 pro-apoptotic gene; TRAIL; 32, 49, 50 prodrug activation platform such as herpes simplex kinase-thymidine kinase; 51, 52 antiangiogenic agents such as endostatin and carboxylesterase; 53 oncolytic virus 33 and nanoparticles. 54 Although modified MSCs have not been introduced into clinical trials for reasons that will be discussed in the latter section, neural stem cells modified with the yeast cytosine deaminase gene have been initiated as the first phase I clinical study using modified stem cells against human brain tumors. 55 
CHALLENGES FACED USING MSCs FOR TARGETED CANCER GENE THERAPY
Despite encouraging results from preclinical animal models, the translation of MSCs for clinical use is challenging due to the controversial role of MSCs in the tumor microenvironment. Some reported that MSCs could promote tumor progression, whereas others reported that MSCs exhibited an anti-tumor effect. This difference may be attributed to inherent biological differences in the source of MSCs, the heterogeneity of MSCs, the interaction of MSCs and their secreted factors with the surrounding microenvironment and other parameters such as the dose and time of MSC administration/analysis, the optimal culture condition 56 and so on. In the context of breast cancer studies, Karnoub et al. 57 had concluded that human bone marrow-derived MSCs could enhance breast cancer metastasis. By contrast, Qiao et al. 58 showed that MSCs isolated from human dermis MSCs exerted an inhibitory effect on the growth of similar breast tumor cells. In brain tumor studies, umbilical cord blood-derived MSCs have been shown to induce apoptosis in glioma cells; however, in the same study, adipose-derived MSCs enhance the growth in GBM probably because MSCs from adipose secrete more proangiogenic factors and could inhibit TRAIL activation in the presence of chemokine CXCL12 (also known as stromal-derived factor-1). 59 In another study, MSCs derived from adipose tissue demonstrated greater tolerance to oxidative stress and serum-deprived apoptosis when compared with bone marrow-derived MSCs. 60 This difference in responding to stress signals could contribute to why co-culturing of adipose-derived MSCs with human glioma cells leads to better survival and proliferation in one study, 61 whereas in the other study, bone marrow-derived MSCs co-cultured with human glioma cells inhibit tumor cell proliferation. 62 Despite the difference, both adipose-and bone marrow-derived MSCs are reported to exhibit comparable tumor tropism towards glioma. 63 Another reason that could explain the biological difference is attributed to the diverse repertoire of distinct subpopulations that exist in vivo. Heterogeneity of MSCs may be further distinguished by cell populations from different donors, that is, intra-population or within the same isolate. 64 Currently, there is no specific marker that can differentiate one subpopulation from the other, as well as, a lack of consensus in the stem cells field on a stringent definition of an MSC. It is interesting that Waterman et al. 65 could separate a mixed pool of MSCs, from at least six different donors, into two distinct phenotypes MSC1 and MSC2. MSC1 could attenuate tumor growth and metastasis, whereas MSC2 promote tumor growth. Last but not least, MSCs are known to secrete a vast array of proteins including growth factors, cytokines, chemokines and so on, which regulate their biology in an autocrine or paracrine manner in accordance to the surrounding tumor microenvironment. 66, 67 MSCs have been shown to inhibit cancer cell proliferation through the secretion of dickkopf-1 (Dkk-1), an inhibitor of the canonical Wnt signaling pathway. 58, 68 Guo et al. 69 have shown that the levels of expression of DKK1 in human glioma cells are dependent on the microenvironment such as hypoxia or the intercellular crosstalk with bone marrow-derived stem cells. Another way MSCs can mediate tumor growth is via secretion of exosomes, which are formed by inward budding of late endosomes, leading to the formation of vesicle-containing endosomes known as multivesicular bodies. These bodies subsequently fuse with the plasma membrane and are released into the extracellular space. 70 In a recent study, exosomes isolated from normal and multiple myeloma (MM) cells were shown to affect MM cell proliferation in an opposite manner in vitro and in vivo. 71 Normal bone marrow-derived MSC exosomes inhibited the growth of MM cells, whereas those derived from MM were shown to promote tumor growth. Further analysis showed that MM bone marrow-derived MSC exosomes had higher levels of interleukin-6, with a lower content of the tumor suppressor miR15a. It may be of interest to note that Ragni et al. 72 have recently demonstrated highly restricted microRNA profiles in adiposetissue-derived MSCs, bone-marrow-derived MSCs and cord-blood derived MSCs. The differences in microRNAs and their sourcespecific gene targets in the microenvironment could also provide some new insights in explaining the biological differences. Other possible factors include the culture condition of MSCs and the cryopreservation method. It has been reported that the osmotic and temperature shock upon cryostorage retrieval of MSCs altered the intracellular pH, intracellular mitochondria aggregation and the signaling associated with adhesion. 73 By contrast, others have reported that cryopreservation does not alter the biological properties of stem cells. 74 Although ongoing investigative directions aimed at advancing our knowledge of the relationship between MSCs and tumor cells, the development of systemic cell-free therapeutics are becoming a new concept in regenerative medicine.
SECRETOMES FROM MSCs
In GBM, microvesicles shed by the tumor cells expressing the mutant epidermal growth factor receptor variant III (EGFRvIII) were readily taken up by EGFRvIII-negative cells and thus enhanced anchorage-independent growth. 75 From the perspective of MSCs, the first report of the cytoprotective effect of MSCs was reported by Gnecchi et al. 76 In the context of cardiac regeneration, they have found significant cardiac functional improvement in less than 72 h post intramyocardial injection of Akt-modified MSCs in a rat model. Although low levels of cellular fusion and differentiation may account for the enhanced survival of myocytes, these events were so uncommon that the group has attributed the enhanced cardiac function to paracrine factors expressed by the MSCs. 77, 78 Lim and colleagues 79 have found that the observed cardio-protective effect can be attributed to the stimulation of angiogenesis via increased capillary density and reduced myocardial infarct size. 79 In the setting of renal injury, Humphreys et al. 80 have demonstrated that repopulation of the renal tubules following acute kidney injury is modulated by the surviving uninjured tubular cells. Similar to myocardial infarction model, reno-protective effects were observed in the absence of MSCs differentiating into epithelial cells. 81, 82 The protection may arise through ameliorating oxidative stress and cell apoptosis. 83 Exosomes derived from MSCs could also reduce the surface fibrous capsules and reduce hepatic inflammation and collagen deposition in carbon tetrachloride (CCI 4 )-induced fibrotic liver. 84 In the same study, epithelial-to-mesenchymal transition-associated markers were reduced after transplantation of the exosomes from MSCs, thus providing protection to the hepatocytes. Further support for the paracrine action of MSCs is provided by showing that conditioned medium (CM) derived from MSCs exhibits similar benefits as the cells of origin. 85 CM derived from the MSCs have been shown to increase survival, proliferation and migration of endothelial cells in the setting of wound healing capacity. 86 In contrast, the CM-MSCs could inhibit corneal fibroblasts from progressing through the cell cycle. In addition, the migratory and contractibility of corneal fibroblasts were also inhibited. 87 In a rat model of fulminant, CM-MSCs can functionally divert immune cells from the injured organ. 88 The effect of CM-MSCs in the tumor microenvironment is beginning to emerge. One recent study reported that MSCs have a dual role in tumor growth in vitro and in vivo. 89 Though the focus is not on the CM, they did report that many of the cell proliferation-associated proteins were inhibited in the tumor cells treated with CM-MSC. In another study, Gauthaman et al. 90 , reported that CM derived from human Wharton's jelly stem cell promotes apoptosis and autophagy. 90 In our laboratories, we have consistently observed that direct cell cultures of adult MSCs with tumor cells exhibited an inhibitory effect on the growth of tumor cells in vitro and in vivo.
62 Similar effects can be observed through the paracrine actions of MSCs. At present, the physiological role of MSC derived-vesicles and condition media, and how they may modulate tumorigenesis is not well understood. It is thus important to identify and study these factors in depth before any clinical translation. So far, repeated administration of allogenic microvesicles derived from MSCs has not been shown to elicit any immune responses as they do not express any histocompatibility antigens. However, other challenges such as the large-scale production of these clinicalgrade reagents, the choice of adequate quality controls at each step of the production and so on remain to be addressed.
CONCLUDING REMARKS
It remains a formidable challenge to identify an effective agent/ vector that could efficiently inhibit (i) the growth of cancer cells; (ii) angiogenesis; (iii) metastasis; (iv) tumor-associated inflammation; (v) inactivate proliferative signal and (vi) induce specific apoptosis. Although it is necessary to exercise significant caution while considering these cells for cancer treatment, MSCs do possess unique features (inherent tumor tropism, anti-inflammatory and immunosuppressive properties) that are not commonly found in current anticancer agents. Therefore, it is of great clinical importance for the field to resolve many of the unanswered questions involving using MSCs for cancer therapy before their clinical translation.
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